A Summary of the ADVANCE Trial - Diabetes Care（推进试验的总结u2014u2014糖尿病护理）.pdfVIP

D I A B E T E S A N D C A R D I O V A S C U L A R D I S E A S E A Summary of the ADVANCE Trial SIMON R. HELLER, DM, FRCP over 10,000 patients with established ON BEHALF OF THE ADVANCE type 2 diabetes in a factorial design (Table COLLABORATIVE GROUP* 1), resulting in treatment in four catego- ries: 1) intensive glucose lowering (in- cluding gliclazide MR) and additional he publication of the U.K. Prospec- topril or atenolol could reduce micro- “routine” BP lowering (perindopril/ tive Diabetes Study (UKPDS) in vascular disease (3). indapamide combination), 2) standard T1998 helped to shape the manage- In a subsequent study, the UKPDS in- glucose therapy and routine BP lowering, ment of type 2 diabetes in recent years (1). vestigators presented the rates of both mi- 3) intensive glucose lowering and pla- The study demonstrated several points. cro- and macrovascular disease according cebo; and 4) standard glucose therapy First, sulfonylureas are as safe as insulin in to the achieved levels of A1C during the and placebo (6). controlling blood glucose. Second, met- study (4). They showed a linear relation- Patients were included if they had formin reduced cardiovascular disease in ship between A1